{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:12:25Z","timestamp":1778274745304,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2025-02303394"],"award-info":[{"award-number":["RS-2025-02303394"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["24H1650"],"award-info":[{"award-number":["24H1650"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["24H1660"],"award-info":[{"award-number":["24H1660"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["24H1710"],"award-info":[{"award-number":["24H1710"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["25M2540"],"award-info":[{"award-number":["25M2540"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["25M3010"],"award-info":[{"award-number":["25M3010"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2025.201120","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:02:36Z","timestamp":1765958556000},"page":"201120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-\u03b2 and PD-L1 inhibitors"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0116-2285","authenticated-orcid":false,"given":"Min-Jung","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hue","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Na","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Pyo","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Ri","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seulki","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Min","family":"Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Kyung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-1829","authenticated-orcid":false,"given":"Hark Kyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201120_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2025.201120_bib2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201120_bib3","article-title":"Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201120_bib4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201120_bib5","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201120_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201120_bib7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12967-024-04990-6","article-title":"CD19\/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia","volume":"22","author":"Yang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2025.201120_bib8","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","article-title":"Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors","volume":"14","author":"Castiglioni","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201120_bib9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","article-title":"Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy","volume":"21","author":"Chen","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201120_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2025.201120_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2338558","article-title":"Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-\u03b2 and PD-L1 enhances antitumor responses","volume":"13","author":"Tapia-Galisteo","year":"2024","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201120_bib12","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.13569","article-title":"Established gastric cancer cell lines transplantable into C57BL\/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth","volume":"109","author":"Yamamoto","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2025.201120_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7150\/jca.35821","article-title":"Knockdown of serine\/threonine-protein kinase 24 promotes tumorigenesis and myeloid-derived suppressor cell expansion in an orthotopic immunocompetent gastric cancer animal model","volume":"11","author":"Hsu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201120_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.tranon.2018.11.010","article-title":"The Role of TGF-\u03b2 and Its Receptors in Gastrointestinal Cancers","volume":"12","author":"Luo","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2025.201120_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201120_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3810","article-title":"Targeting the TGF\u03b2 signalling pathway in disease","volume":"11","author":"Akhurst","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2025.201120_bib19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6603877","article-title":"Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients","volume":"97","author":"Hawinkels","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib20","doi-asserted-by":"crossref","first-page":"djt369","DOI":"10.1093\/jnci\/djt369","article-title":"TGF-\u03b2: duality of function between tumor prevention and carcinogenesis","volume":"106","author":"Principe","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2025.201120_bib21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nrd1580","article-title":"Development of TGF-beta signalling inhibitors for cancer therapy","volume":"3","author":"Yingling","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2025.201120_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ccell.2022.06.010","article-title":"Pan-cancer proteomic map of 949 human cell lines","volume":"40","author":"Gon\u00e7alves","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201120_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0959-8049(02)00008-4","article-title":"Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma","volume":"38","author":"Tot","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers15040998","article-title":"MUC1 expressions and its prognostic values in US gastric cancer patients","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2025.201120_bib25","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3892\/ol.2015.3483","article-title":"Significance of MUC1 expression in biopsy specimens of submucosal invasive gastric carcinoma: The association with lymph node metastasis","volume":"10","author":"Lee","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omton.2025.201120_bib26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mc.22226","article-title":"Establishment and characterization of metastatic gastric cancer cell lines from murine gastric adenocarcinoma lacking Smad4, p53, and E-cadherin","volume":"54","author":"Park","year":"2015","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.omton.2025.201120_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccell.2018.12.003","article-title":"Proteogenomic characterization of human early-onset gastric cancer","volume":"35","author":"Mun","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201120_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5230\/jgc.2020.20.e33","article-title":"Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric cancer","volume":"20","author":"Kim","year":"2020","journal-title":"J. Gastric Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib29","doi-asserted-by":"crossref","first-page":"oyae238","DOI":"10.1093\/oncolo\/oyae238","article-title":"Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression","volume":"30","author":"Kwak","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.omton.2025.201120_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.omton.2025.201120_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jjco\/hyab054","article-title":"Patterns of immune infiltration in gastric cancer and their clinical significance","volume":"51","author":"Jin","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201120_bib32","article-title":"Immune Infiltration in Gastric Cancer Microenvironment and Its Clinical Significance","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omton.2025.201120_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13059-022-02828-2","article-title":"Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment","volume":"23","author":"Kang","year":"2022","journal-title":"Genome Biol."},{"key":"10.1016\/j.omton.2025.201120_bib34","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1128\/IAI.00533-13","article-title":"Requirement and Redundancy of the Src Family Kinases Fyn and Lyn in Perforin-Dependent Killing of Cryptococcus neoformans by NK Cells","volume":"81","author":"Oykhman","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.omton.2025.201120_bib35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/cmi.2016.28","article-title":"Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression","volume":"14","author":"Zhang","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2025.201120_bib36","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.4049\/jimmunol.168.7.3155","article-title":"Syk regulation of phosphoinositide 3-kinase-dependent NK cell function","volume":"168","author":"Jiang","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.201120_bib37","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1007\/s12094-023-03211-8","article-title":"Comprehensive analysis and identification of prognostic biomarkers and immunotherapeutic targets in the NADPH oxidase family (and its regulatory subunits) in pancreatic ductal adenocarcinoma","volume":"25","author":"Guo","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.omton.2025.201120_bib38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41416-018-0008-y","article-title":"Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models","volume":"118","author":"Shimada","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0925-4773(96)00609-0","article-title":"Pancreatic-duodenal homeobox 1 \u2013 role in gastric endocrine patterning","volume":"60","author":"Larsson","year":"1996","journal-title":"Mech. Dev."},{"key":"10.1016\/j.omton.2025.201120_bib40","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201120_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2025.201120_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","article-title":"Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study","volume":"36","author":"Qi","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.omton.2025.201120_bib43","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201120_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-016-0285-y","article-title":"Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level","volume":"9","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201120_bib45","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.201120_bib46","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201120_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.201120_bib48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2025.201120_bib49","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2025.201120_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 blockade enhances anti-tumor efficacy of NK cells","volume":"7","author":"Oyer","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2025.201120_bib51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","article-title":"Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse","volume":"4","author":"Hingorani","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201120_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ng747","article-title":"Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer","volume":"29","author":"Jonkers","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2025.201120_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:26:20Z","timestamp":1778271980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329925001894"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201120","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-\u03b2 and PD-L1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201120"}}